RN
RNA.US Atrium Therapeutics, Inc. Common Stock
- Market cap
- USD 140M
- P/E
- -
- P/B
- 0.79x
- ROE
- -26.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RNA.US undervalued?
Graham numberThe Graham number of Atrium Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Atrium Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Atrium Therapeutics, Inc. Common Stock yet.
Atrium Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of gene…
Full company profileAtrium Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Atrium Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.4M | 13.1M | 379K | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M | 10.9M | 18.6M | 50.6M |
| Gross Profit | - | - | -8.06M | 2.32M | 6.79M | 9.33M | 9.22M | 7.46M | 10.9M | 18.6M | 20.7M |
| Operating Income | - | - | -10.5M | -17.3M | -44.3M | -118M | -179M | -236M | -379M | -76.8M | -62.0M |
| EBITDA | - | - | -10.1M | -17.0M | -43.9M | -117M | -178M | -233M | -376M | -76.5M | -56.9M |
| Net Income | - | - | -11.9M | -24.7M | -44.0M | -117M | -169M | -212M | -322M | -76.7M | -54.8M |
| EPS | - | - | -0.58 | -0.66 | -2.03 | -2.83 | -3.24 | -2.91 | -2.89 | -4.48 | -3.22 |
| Balance Sheet | |||||||||||
| Total Assets | 62.4M | 125M | 3.98M | 96.9M | 334M | 428M | 639M | 629M | 1.56B | 278M | 264M |
| Total Liabilities | 41.9M | 38.0M | 45.1M | 162M | 27.7M | 46.2M | 60.7M | 128M | 139M | 71.1M | 59.0M |
| Shareholders' Equity | 20.5M | 87.1M | -41.1M | -65.4M | 306M | 381M | 578M | 501M | 1.42B | 207M | 205M |
| Cash & Short-term Investments | 53.7M | 113M | 3.09M | 94.6M | 328M | 406M | 611M | 595M | 1.50B | 270M | 232M |
| Total Debt | - | - | 10.3M | 4.94M | 938K | 11.7M | 10.7M | 9.85M | 6.80M | 3.67M | 679K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | -9.66M | 2.49M | -37.1M | -94.8M | -136M | -119M | -301M | -41.1M | -80.6M |
| Capital Expenditure | 309K | 834K | 49.0K | 235K | 1.09M | 3.74M | 2.82M | 4.23M | 7.07M | 1.45M | 3.40M |
| Free Cash Flow | - | - | -9.70M | 2.26M | -38.2M | -98.6M | -139M | -123M | -308M | -42.6M | -84.0M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -14.4% | -30.8% | -29.2% | -42.4% | -22.6% | -37.0% | -26.7% |
| ROA | - | - | -299.7% | -25.5% | -13.2% | -27.4% | -26.5% | -33.8% | -20.6% | -27.5% | -20.8% |
| Net Profit Margin | - | - | -3,148.8% | -1,066.6% | -648.0% | -1,258.5% | -1,833.0% | -2,219.9% | -2,957.7% | -411.9% | -108.2% |
| Debt to Equity | - | - | - | - | 0.00x | 0.03x | 0.02x | 0.02x | 0.00x | 0.02x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Atrium Therapeutics, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 444K | 0.02 | - |
| 2019 | USD 106K | 0.00 | - |
| 2018 | USD 106K | 0.01 | - |
| 2013 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Atrium Therapeutics, Inc. Common Stock
- Insiders 3.30%
- Institutions 65.86%
- Public & others 30.84%
- Shares outstanding 21.6M
- Free float 19.5M
Top funds holding RNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.77M | 1.79% | 0.00% | Feb 2026 |
| BlackRock Event Driven Equity Instl | 1.75M | 1.13% | 0.00% | Jan 2026 |
| iShares Russell 2000 Growth ETF | 888K | 0.57% | 0.00% | Feb 2026 |
| Vanguard Russell 2000 ETF | 551K | 0.36% | -3.11% | Jan 2026 |
| Vanguard Health Care ETF | 330K | 0.21% | -0.04% | Jan 2026 |
| Schwab Small Cap Index | 292K | 0.19% | +1.36% | Jan 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 190K | 0.12% | +229.95% | Jan 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 187K | 0.12% | +502.97% | Jan 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 178K | 0.11% | 0.00% | Feb 2026 |
| Nuveen Small Cap Blend Idx R6 | 141K | 0.09% | 0.00% | Jan 2026 |
| EQ/2000 Managed Volatility IB | 125K | 0.08% | 0.00% | Jan 2026 |
| BlackRock Advantage Small Cap Core Instl | 117K | 0.08% | +0.20% | Jan 2026 |
| Return Stacked Bonds & Mrg Arbtrg ETF | 106K | 0.07% | 0.00% | Feb 2026 |
| BlackRock Health Sciences Opps Inv A | 100K | 0.06% | 0.00% | Jan 2026 |
| Vanguard Russell 2000 Growth ETF | 97.9K | 0.06% | +4.41% | Jan 2026 |
| Nuveen Equity Index R6 | 94.5K | 0.06% | 0.00% | Jan 2026 |
| Vanguard Total World Stock ETF | 84.9K | 0.05% | +1.66% | Jan 2026 |
| Schwab Total Stock Market Index | 70.4K | 0.05% | +1.73% | Jan 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 68.7K | 0.04% | 0.00% | Jan 2026 |
| EQ/Small Company Index IB | 63.1K | 0.04% | 0.00% | Jan 2026 |
Top institutions holding RNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Corsicana & Co. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sageview Advisory Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Atrium Therapeutics, Inc. Common Stock company profile
- Company name
- Atrium Therapeutics, Inc. Common Stock
- Ticker
- RNA.US
- Exchange
- USA Stocks
- Listed since
- Jun 28, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 511
- Fiscal year end
- December
- Address
- 10578 Science Center Drive, San Diego, CA, United States, 92121
- Phone
- 619 876 0700
- Website
- atriumtherapeutics.com
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.
Atrium Therapeutics, Inc. Common Stock management
6- Ms. Kathleen P. GallagherPresident, CEO & Director · born 1981
- Mr. Brendan WinslowChief Financial Officer · born 1988
- Dr. Husam Younis Ph.D., Pharm.D.Chief Scientific Officer · born 1974
- Ms. Stephanie KenneyChief Corporate Affairs Officer · born 1978
- Dr. Steven George Hughes M.B.A., M.D.Chief Medical Officer · born 1967
- Ms. Rocio Martin HoyosChief Strategy Officer · born 1983